Apheon Buys Majority Stake in Hager & Meisinger, Targets U.S. Dental Expansion

European private-equity firm Apheon has acquired a majority stake in Hager & Meisinger Group, the manufacturer behind the Meisinger and Jota dental-instrument brands.

The company's co-CEOs and existing shareholders, Dr. Burkard Höchst and Sebastian Voss, will retain meaningful ownership and remain involved in the business. Financial terms and transaction value were not disclosed.

What Apheon Acquired

Hager & Meisinger is a vertically integrated dental manufacturer headquartered in Germany, with production operations in Germany and Switzerland.

The group offers more than 12,000 product references across rotary instruments, bone management, implantology and digital dentistry. Its products are sold to dental practices, oral surgeons and laboratories in more than 100 countries.

Apheon's investment brings together two established brands:

• Meisinger, known for rotary instruments, bone-management systems and implantology products; and
• Jota, a Swiss manufacturer of rotary dental instruments.

The company intends to continue investing in its core product lines while using Apheon's support to accelerate organic growth and pursue selective acquisitions.

Why It Matters to the U.S. Dental Market

The most important part of the announcement is geographic: Hager & Meisinger and Apheon explicitly identified the United States as a priority expansion market.

That makes this more than a European ownership change. The new capital structure gives the manufacturer additional resources to expand commercial coverage, strengthen distributor relationships and potentially acquire complementary dental-product businesses.

For U.S. practices and DSOs, increased competition among instrument and implant-workflow suppliers could affect:

• distributor choice and product availability;
• enterprise pricing and purchasing agreements;
• standardization of rotary and surgical systems;
• clinical training and support; and
• the pace at which specialized European products enter U.S. workflows.

The group already has the product breadth to serve general dentistry, oral surgery, laboratories and implant workflows. The strategic question is whether Apheon can convert that catalog and manufacturing base into stronger U.S. distribution and account coverage.

The Buy-and-Build Signal

Apheon is not presenting the investment as a passive financial holding. The firm cited its buy-and-build experience, and Hager & Meisinger said it plans to pursue selective acquisitions alongside organic growth.

That creates two possible paths.

The company could acquire adjacent product capabilities in areas such as implantology, bone management or digital dentistry. It could also buy commercial infrastructure that accelerates access to dentists and DSOs in target markets.

Either path would contribute to further consolidation among dental manufacturers. As procurement becomes more centralized inside large dental groups, suppliers benefit from offering a broader portfolio, dependable fulfillment and enterprise-level commercial support.

What to Watch Next

Several developments will show whether the investment changes Hager & Meisinger's U.S. position:

1. Distribution strategy: Does the company add direct sales capacity, deepen existing distributor partnerships or combine both approaches?
2. U.S. acquisitions: Will Apheon use M&A to acquire products, regulatory clearances or customer access?
3. DSO contracting: Does the group pursue national agreements with multi-location dental organizations?
4. Portfolio integration: Can Meisinger and Jota present a unified commercial offering without diluting their specialist brands?
5. Digital dentistry: Will investment expand beyond instruments into more connected procedural and digital workflows?

Avized Take

This transaction matters because it pairs a broad, vertically integrated dental manufacturer with a private-equity sponsor that has both capital and explicit acquisition experience.

For U.S. operators, the near-term impact may be limited. The longer-term signal is more important: Hager & Meisinger now has a financial partner backing a deliberate U.S. expansion strategy. If that strategy includes acquisitions or enterprise DSO contracts, competition in dental instruments, implantology and procedural workflows could shift quickly.

Primary source: Apheon announcement, October 6, 2026